A Phase Ia Clinical Trial to Assess the Safety and Immunogenicity of the Blood-stage Malaria Candidate Vaccines RH5.1 in Matrix-M and R78C in Matrix-M in Healthy UK Adults

EARLY_PHASE1Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 13, 2023

Primary Completion Date

March 31, 2026

Study Completion Date

March 31, 2026

Conditions

Malaria, Falciparum

Interventions

BIOLOGICAL

Matrix M with R78C and/or RH5.1

50 µg of Matrix-M adjuvant with R78C and/or RH5.1 at different doses and timepoints

Trial Locations (1)

CCVTM, University of Oxford, Churchill Hospital, Oxford

All Listed Sponsors

lead

University of Oxford

OTHER